Extrapyramidal symptoms and antidepressant drugs: Neuropharmacological aspects of a frequent interaction in the elderly

Molecular Psychiatry

Volumn 6, Issue 2, 2001, Pages 134-142

  Govoni, S ^a   Racchi, M ^a   Masoero, E ^a   Zamboni, M ^b   Ferini Strambi, L ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b Institute San Raffaele   (Italy)

Author keywords

Antidepressant drugs; Depression; Elderly; Extrapyramidal symptoms; Movement disorders; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; AMINEPTINE; AMISULPRIDE; AMITRIPTYLINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; CIMETIDINE; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE; DOXEPIN; FLUOXETINE; HOMOVANILLIC ACID; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MUSCIMOL; NORADRENALIN; PHYSOSTIGMINE; ROXINDOLE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AFFECTIVE NEUROSIS; AGED; AGING; ALZHEIMER DISEASE; BASAL GANGLION; CLINICAL TRIAL; DEPRESSION; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; GERIATRIC PATIENT; HUMAN; MOTOR DYSFUNCTION; NEUROBIOLOGY; NEUROPHARMACOLOGY; NEUROTRANSMISSION; PARKINSONISM; PRIORITY JOURNAL; REVIEW;

AGED; ANTIDEPRESSIVE AGENTS; BASAL GANGLIA DISEASES; DEPRESSION; DRUG INTERACTIONS; HUMANS;

EID: 0035115039     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000801     Document Type: Review

References (69)

1. Treatment of depression in late life
2. Depression in the aged: Diagnosis and treatment
3. Extrapyramidal symptoms associated with cyclic antidepressant treatment: A review of the literature and consolidating hypotesis
4. Managements of psychiatric symptoms of Parkinson's disease
5. Risk factors for depression in Parkinson's disease
6. Aging and the basal ganglia
7. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals
8. Parkinson's disease. Second of two parts
9. Post mortem studies in Parkinson's disease - Is it possible to detect brain areas for specific symptoms?
10. Depression in Parkinson's disease: Brainstem midline alteration on transcranial sonography and magnetic resonance imaging
11. Parkinson's disease and depression: Evidence for an alteration of the basal limbic system detected by transcranial sonography
12. The mesolimbic dopamine system as a target for rapid antidepressant action
13. The catecholamine hypothesis of affective disorders: A review of supporting evidence
14. Noradrenaline (Norepinephrine) and depression. Role in aetiology and therapeutic implications
15. Mechanism of action of antidepressant medication
16. Novel pharmacological approaches to the treatment of depression
17. cAMP-dependent phosphorylation system after short and long-term administration of moclobemide
18. Effects of fluvoxamine on the protein phosphorylation system associated with rat neuronal microtubules
19. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus
20. Long-term blockade of serotonin reuptake affects synaptotagmin phosphorylation in the hippocampus
21. The role of noradrenaline in depression: A review
22. Biochemical hypotheses on antidepressant drugs: A guide for clinicians or a toy for pharmacologists?
23. Depression and antidepressant therapy: Receptor dynamics
24. A role for 5-HT in the action of antidepressant drugs
25. Neurochemical alterations of serotonergic neuronal systems in depression
26. Aminergic studies and cerebrospinal fluid cations in suicide
27. Antidepressants. Current concepts of mode of action
28. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients
29. CSF amine metabolites in depression
30. Mechanisms of action of antidepressants
31. Platelet serotonin markers and depressive symptomatology
32. Platelet serotonin-2 receptor binding sites in depression and suicide
33. Studies on the serotonin transporter in platelets
34. 3H]-paroxetine binding in depressed patients
35. 3H] paroxetine to platelets of depressed patients: Seasonal differences and effects of diagnostic classification
36. Dysthymia and depressive disorders - Dopamine hypothesis
37. Slowness of movement in melancholic depression
38. Dopamine and depression. Therapeutic implications
39. Sensitivity to ageing of the limbic dopaminergic system: A review
40. Dopamine and depression
41. Depression and Parkinson's disease: Possible role of serotonergic mechanisms
42. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition
43. Chronic central nervous system effects of acute organophosphate pesticide intoxication
44. Acute stress facilitates long-lasting changes in cholinergic gene expression
45. Tardive dyskinesia
46. Parkinsonism associated with fluoxetine and cimetidine: A case report
47. Neurotransmitters changes in human brain during aging
48. Complex movement disorders induced by fluoxetine
49. Antidepressant-induced tardive dyskinesia: Review and case report
50. Fluoxetine induced dyskinesia
51. Sertraline for the treatment of depression in Parkinson's disease
52. Tricyclic antidepressant-induced extrapyramidal side effects
53. Agitated depression as a mixed state and the problem of melancholia
54. Mechanism of action of antidepressant treatments: Implication for etiology and treatment of depressive disorders
55. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications
56. Central dopaminergic transmission is selectively increased in the limbic system of rats chronically exposed to antidepressants
57. The effects of L-tryptophan on haloperidol-induced movement disorder in the rat
58. Adaption of N-methil-D-aspartate (NMDA) receptors following antidepressant treatment: Implication for the pharmacotherapy of depression
59. Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
60. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons
61. 3 dopamine receptor antagonist activity and limbic selectivity
62. 3 receptor antagonist with both presynaptic and limbic selectivity
63. Amisulpride. A review of its clinical potential in dysthymya and double depression
64. Amisulpride versus amineptine and placebo for the treatment of dysthymia
65. Amisulpride versus imipramine and placebo in dysthymia and major depression
66. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study
67. Treatment resistant depression: Methodological overview and operational criteria
68. Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex
69. Regulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors